Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center For Human Genetics And Laboratory Diagnostics, |
RCV002814364 | SCV003035450 | uncertain significance | Hyperparathyroidism 4 | 2022-04-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002776558 | SCV003589349 | uncertain significance | Inborn genetic diseases | 2024-11-14 | criteria provided, single submitter | clinical testing | The c.523A>T (p.I175F) alteration is located in exon 4 (coding exon 4) of the GCM2 gene. This alteration results from a A to T substitution at nucleotide position 523, causing the isoleucine (I) at amino acid position 175 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005044994 | SCV005673993 | uncertain significance | Hyperparathyroidism 4; Hypoparathyroidism, familial isolated, 2 | 2024-04-19 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003963362 | SCV004782114 | uncertain significance | GCM2-related disorder | 2024-02-02 | no assertion criteria provided | clinical testing | The GCM2 c.523A>T variant is predicted to result in the amino acid substitution p.Ile175Phe. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0026% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |